Ben-Fillippo Krippendorff
Ben-Fillippo Krippendorff
Unknown affiliation
Verified email at
Cited by
Cited by
G-quadruplex DNA as a molecular target for induced synthetic lethality in cancer cells
KIE McLuckie, M Di Antonio, H Zecchini, J Xian, C Caldas, ...
Journal of the American Chemical Society 135 (26), 9640-9643, 2013
Mechanism-based inhibition: deriving KI and kinact directly from time-dependent IC50 values
BF Krippendorff, R Neuhaus, P Lienau, A Reichel, W Huisinga
SLAS Discovery 14 (8), 913-923, 2009
Influence of molecular size on tissue distribution of antibody fragments
Z Li, BF Krippendorff, S Sharma, AC Walz, T Lavé, DK Shah
MAbs 8 (1), 113-119, 2016
Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis
BF Krippendorff, K Kuester, C Kloft, W Huisinga
Journal of pharmacokinetics and pharmacodynamics 36 (3), 239-260, 2009
Optimizing classification of drug-drug interaction potential for CYP450 isoenzyme inhibition assays in early drug discovery
BF Krippendorff, P Lienau, A Reichel, W Huisinga
Journal of biomolecular screening 12 (1), 92-99, 2007
Quantification of IgG monoclonal antibody clearance in tissues
MJ Eigenmann, L Fronton, HP Grimm, MB Otteneder, BF Krippendorff
MAbs 9 (6), 1007-1015, 2017
Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy
F Bauss, M Lechmann, BF Krippendorff, R Staack, F Herting, M Festag, ...
Molecular oncology 10 (8), 1317-1329, 2016
Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells
Y Lin, FM Richards, BF Krippendorff, JL Bramhall, JA Harrington, ...
British journal of cancer 107 (10), 1692-1701, 2012
Interstitial IgG antibody pharmacokinetics assessed by combined in vivo‐ and physiologically‐based pharmacokinetic modelling approaches
MJ Eigenmann, TV Karlsen, BF Krippendorff, O Tenstad, L Fronton, ...
The Journal of physiology 595 (24), 7311-7330, 2017
Influence of Molecular size on the clearance of antibody fragments
Z Li, BF Krippendorff, DK Shah
Pharmaceutical research 34 (10), 2131-2141, 2017
Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer
A Courtin, FM Richards, TE Bapiro, JL Bramhall, A Neesse, N Cook, ...
PloS one 8 (6), e67330, 2013
Capacity limits of asialoglycoprotein receptor-mediated liver targeting
C Bon, T Hofer, A Bousquet-Mélou, MR Davies, BF Krippendorff
MAbs 9 (8), 1360-1369, 2017
Predicting the F (ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling
BF Krippendorff, DA Oyarzún, W Huisinga
Journal of pharmacokinetics and pharmacodynamics 39 (2), 125-139, 2012
A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer
G Kollmorgen, K Palme, A Seidl, S Scheiblich, F Birzele, S Wilson, ...
Scientific reports 7 (1), 1-13, 2017
RG7787-a novel de-immunized PE based fusion protein for therapy of mesothelin-positive solid tumors
G Niederfellner, F Bauss, S Imhof-Jung, F Hesse, S Kronenberg, R Staak, ...
Cancer Research 74 (19_Supplement), 4510-4510, 2014
The EGFR demonstrates linear signal transmission
DA Oyarzún, JL Bramhall, F López-Caamal, FM Richards, DI Jodrell, ...
Integrative biology 6 (8), 736-742, 2014
Ligand accumulation counteracts therapeutic inhibition of receptor systems
BF Krippendorff, D Oyarzún, W Huisinga
Influence of molecular size on tissue distribution of antibody fragments. MAbs 8, 113–119
Z Li, BF Krippendorff, S Sharma, AC Walz, T Lave, DK Shah
Target‐Driven Pharmacokinetics of Biotherapeutics
W Huisinga, S Fuhrmann, L Fronton, BF Krippendorff
Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and …, 2010
Anti-TPBG antibodies and methods of use
S Dengl, S Fenn, J Fischer, T Friess, S Imhof-Jung, B Krippendorff, ...
US Patent 10,434,184, 2019
The system can't perform the operation now. Try again later.
Articles 1–20